BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15751502)

  • 1. Patient-specific vaccine therapy for non-Hodgkin lymphoma.
    Hohenstein M; King SE; Fiore JM; O'Brien T; Blumel S
    Clin J Oncol Nurs; 2005 Feb; 9(1):85-90. PubMed ID: 15751502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
    J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
    J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M; Gocke CD; Kobrin CB; Benko FA; Sternas LA; Pennington R; Watson TM; Reynolds CW; Gause BL; Duffey PL; Jaffe ES; Creekmore SP; Longo DL; Kwak LW
    Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiotype vaccine strategies for treatment of follicular lymphoma.
    Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
    Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine.
    Ansell SM; Suman VJ
    J Clin Oncol; 2011 Jul; 29(20):2748-9. PubMed ID: 21632499
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
    Bendandi M
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
    Reinis M
    Curr Opin Mol Ther; 2008 Oct; 10(5):526-34. PubMed ID: 18830928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccine strategies get bigger and better.
    de Gruijl TD; Curiel DT
    Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
    Vose J
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
    Longo DL
    J Natl Cancer Inst; 2006 Sep; 98(18):1263-5. PubMed ID: 16985240
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
    Maloney DG
    J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
    [No Abstract]   [Full Text] [Related]  

  • 19. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
    Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
    Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R
    Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.